ZEVRA THERAPEUTICS INC. - COMMON STOCK

Zevra Therapeutics Announces Resubmission of Arimoclomol New Drug Application to the U.S. Food and Drug Administration

27 Dec 2023 07:30:00 By Nasdaq GlobeNewswire

Zevra Therapeutics Completes Acquisition of Acer Therapeutics in its Journey to Become a Leading Rare Disease Company

20 Nov 2023 07:30:00 By Nasdaq GlobeNewswire

Zevra Therapeutics Reports Corporate Updates and Third Quarter 2023 Financial Results

07 Nov 2023 07:00:00 By Nasdaq GlobeNewswire

Zevra Therapeutics to Report Third Quarter 2023 Results on November 7, 2023, at 8:00 a.m. ET

31 Oct 2023 07:30:00 By Nasdaq GlobeNewswire

Zevra Therapeutics Celebrates and Supports Global Niemann-Pick Disease Awareness Day on October 19th and Niemann-Pick Disease Awareness Month Throughout October

19 Oct 2023 07:30:00 By Nasdaq GlobeNewswire

Zevra Therapeutics Appoints Neil F. McFarlane as President, Chief Executive Officer and Director

10 Oct 2023 07:30:00 By Nasdaq GlobeNewswire

Zevra Therapeutics to Present at the 52nd Child Neurology Society Annual Meeting

05 Oct 2023 07:30:00 By Nasdaq GlobeNewswire

Zevra Therapeutics Announces Interim Data from the Phase 2 Clinical Trial of KP1077 for Idiopathic Hypersomnia

02 Oct 2023 07:30:00 By Nasdaq GlobeNewswire

Zevra Therapeutics to Participate in the Cantor Global Healthcare Conference

20 Sep 2023 07:30:00 By Nasdaq GlobeNewswire

Zevra Therapeutics Presents Full Data Set on the Cardiovascular Safety and Pharmacokinetics of SDX, the sole API in KP1077, in Healthy Volunteers at Psych Congress 2023

09 Sep 2023 20:00:00 By Nasdaq GlobeNewswire

Zevra Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference

05 Sep 2023 07:30:00 By Nasdaq GlobeNewswire

Zevra Therapeutics to Acquire Acer Therapeutics, Expanding its Rare Disease Portfolio and Adding Commercial Product

31 Aug 2023 07:30:00 By Nasdaq GlobeNewswire

Zevra Therapeutics Reports Corporate Updates and Second Quarter 2023 Financial Results

14 Aug 2023 07:30:00 By Nasdaq GlobeNewswire

Zevra Therapeutics Appoints Thomas Anderson to Board of Directors and Announces Retirement of Matthew R. Plooster

07 Aug 2023 16:45:00 By Nasdaq GlobeNewswire

Zevra Therapeutics to Report Second Quarter 2023 Results on August 14, 2023

02 Aug 2023 07:30:00 By Nasdaq GlobeNewswire

Zevra Therapeutics to Participate in the 2023 NNPDF Family Support and Medical Conference

19 Jul 2023 07:30:00 By Nasdaq GlobeNewswire

Zevra Therapeutics to be Added to Russell 2000® and Russell 3000® Indexes Effective June 26, 2023

20 Jun 2023 07:30:00 By Nasdaq GlobeNewswire

Zevra Therapeutics to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and hosted by M-Vest

13 Jun 2023 08:42:03 By Nasdaq GlobeNewswire

Zevra Therapeutics Presents Design of Phase 2 Clinical Trial Investigating KP1077 for the Treatment of Idiopathic Hypersomnia (IH) at Beyond Sleepy 2023

03 Jun 2023 07:30:00 By Nasdaq GlobeNewswire

Zevra Therapeutics Reports Corporate Updates and First Quarter 2023 Financial Results

15 May 2023 16:05:01 By Nasdaq GlobeNewswire